in diffuse large B-cell lymphoma Mutations of the BCL-6 proto-oncogene disrupt its negative autoregulation
暂无分享,去创建一个
[1] Wei Gu,et al. Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.
[2] W. Gu,et al. Acetylation Inactivates the BCL6 Transcriptional Repressor , 2002 .
[3] R. Gascoyne,et al. Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma. , 2002, Cancer research.
[4] S. Barrans,et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B‐cell lymphoma , 2002, British journal of haematology.
[5] Y. Furukawa,et al. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[6] P. Fernandez,et al. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. , 2001, Genes & development.
[7] D. Fearon,et al. Arrested Differentiation, the Self-Renewing Memory Lymphocyte, and Vaccination , 2001, Science.
[8] L. Pasqualucci,et al. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. , 2000, Cancer research.
[9] N. Miyasaka,et al. Identification of negative regulatory regions within the first exon and intron of the BCL6 gene , 2000, Oncogene.
[10] L. Staudt,et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.
[11] L. Serrano,et al. Engineering stability in gene networks by autoregulation , 2000, Nature.
[12] L. Pasqualucci,et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. , 2000, Blood.
[13] P. Pandolfi,et al. Transcriptional Repression of Stat6-Dependent Interleukin-4-Induced Genes by BCL-6: Specific Regulation of Iɛ Transcription and Immunoglobulin E Switching , 1999, Molecular and Cellular Biology.
[14] Yuichi Nakamura,et al. Analysis of internal deletions within the BCL6 gene in B‐cell non‐Hodgkin's lymphoma , 1999, British journal of haematology.
[15] P. Isaacson,et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. , 1999, Blood.
[16] L. Pasqualucci,et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. Dalla‐Favera,et al. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. , 1998, Genes & development.
[18] U. Storb,et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. , 1998, Science.
[19] P. Pandolfi,et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation , 1997, Nature Genetics.
[20] L. Staudt,et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. , 1997, Science.
[21] D. Leprince,et al. Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation , 1997, Oncogene.
[22] R S Chaganti,et al. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[23] L. Staudt,et al. BCL-6 expression during B-cell activation. , 1996, Blood.
[24] L. Staudt,et al. Transcriptional repression by the proto-oncogene BCL-6. , 1996, Oncogene.
[25] K. Saito,et al. Internal DNA deletion within the BCL-6 gene on untranslocated chromosome in non-Hodgkin's lymphoma with 3q27 abnormality. , 1996, Leukemia.
[26] K. Offit,et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[27] R. Chaganti,et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. , 1995, The EMBO journal.
[28] A. Neri,et al. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators , 1995, Molecular and cellular biology.
[29] S. Mori,et al. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts. , 1995, Blood.
[30] K. Offit,et al. BCL-6 protein is expressed in germinal-center B cells. , 1995, Blood.
[31] M. Ladanyi,et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.
[32] A. Rossi,et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. , 1994, Blood.
[33] K. Offit,et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. , 1994, Blood.
[34] K Offit,et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. , 1993, Science.
[35] H. Tilly,et al. LAZ3, a novel zinc–finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas , 1993, Nature Genetics.
[36] P. H. Rao,et al. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. , 1993, Cancer research.
[37] R. Espinosa,et al. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[38] G. Inghirami,et al. Negative autoregulation of c‐myc gene expression is inactivated in transformed cells. , 1990, The EMBO journal.
[39] L. Penn,et al. Negative autoregulation of c‐myc transcription. , 1990, The EMBO journal.
[40] R. Palmiter,et al. A 12-base-pair DNA motif that is repeated several times in metallothionein gene promoters confers metal regulation to a heterologous gene. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[41] F. Mitelman,et al. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. , 2002, International journal of oncology.
[42] S. Iida,et al. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. , 1998, Blood.
[43] G. Gaidano,et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.